RSV Vaccine on the Horizon

RSV hospitalizes 3 million children under 5 and ~336,000 older adults each year. Efforts to create a vaccine against it have long been elusive—until now. 
4 vaccine candidates and 1 monoclonal antibody treatment are now in late-stage trials, 8 years after the key protein the virus uses to attack human cells was identified by structural biologist Jason McLellan and his team (the same team that identified the spike protein the coronavirus uses).
And the success of the COVID-19 vaccine has made scientists hopeful that RSV vaccine production will soon be kicked into high gear. 

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top